Low-dose IL-2 for chronic hives that don't respond to usual treatment
Part of Immune system & allergy clinical trials.
This study tests a low-dose immune therapy (interleukin-2) for people with chronic hives that don't get better with standard allergy pills. If you are an adult with ongoing hives and itching despite daily antihistamines, this trial might offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 74 years old
- You have had chronic hives for at least 3 months
- You still get hives and itching even after taking allergy pills every day for 2 weeks or more
- You can keep a daily symptom log throughout the study
- You are not pregnant, breastfeeding, or planning to become pregnant within the next 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
This trial tests a new daily pill called TLL-018 (a JAK inhibitor) for people with chronic hives that still cause symptoms despite taking antihistamines. It aims to see how fast it relieves itching and hives.
This study tests a new oral medication (TLL-018) for people with chronic hives that don't fully go away with standard antihistamines. It aims to see if the drug reduces itching and hives better than placebo.
This trial tests an experimental medicine for chronic hives (called chronic spontaneous urticaria). It is for people whose hives still bother them about once or twice a month despite daily treatment, and who do not have heart problems.
This trial tests a new oral medication for chronic spontaneous urticaria (chronic hives). It is a placebo-controlled study, meaning some participants will get the new drug and some will get a placebo (a pill with no active ingredient). The goal is to see if the new drug is safe and how well it works, possibly providing a new treatment option for those whose hives are not controlled by current antihistamines.
This study tests an investigational pill called THB335 for adults whose hives (itchy welts) keep appearing despite taking antihistamines. The goal is to see if this treatment can reduce itching and hives and improve quality of life.
Hear when a new Chronic Spontaneous Uriticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.